Daibao STC Series High-Speed Automatic Tubular Centrifuge for Biopharma & Industrial Separation
GET A FREE QUOTE NOW
Daibao Machinery's STC Series high-speed automatic tubular centrifuge is a GMP-compliant, fully automatic separation solution for biopharmaceutical and industrial applications. With a separation factor of 15,366×g and speeds up to 14,000 rpm, it ensures e
Daibao Machinery Equipment Co., Ltd. is a leading high-tech enterprise specializing in the research, development, and manufacturing of tubular centrifuges. Since acquiring core technology from the Shanghai Centrifugal Machinery Research Institute in 2013, Daibao has pioneered China's first high-speed and fully automatic tubular centrifuges, ending a three-decade reliance on manual discharge processes and filling a critical gap in the industry.
The STC Series represents the pinnacle of Daibao's innovation. Designed for demanding biopharmaceutical applications—such as cell harvest and fermentation broth clarification—this fully automatic tubular centrifuge ensures consistent, high-purity separation with minimal operator intervention. Key features include a separation factor of 15,366×g and speeds up to 14,000 rpm, delivering rapid and efficient separation for both biopharmaceutical and industrial processes.
This GMP-compliant centrifuge is engineered for reliability and ease of use, with automated discharge and cleaning cycles that reduce downtime and labor costs. The STC Series is ideal for applications requiring strict contamination control, such as vaccine production, monoclonal antibody purification, and fine chemical processing.
With a robust design and advanced automation, the Daibao STC Series tubular centrifuge offers a cost-effective solution for high-volume separation needs. Its compact footprint and modular construction allow for easy integration into existing production lines, making it a versatile choice for manufacturers seeking to enhance productivity and product quality.
Product Guide:
Reposted for informational purposes only. Views are not ours. Stay tuned for more.

